View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

   reports
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
03/21/24 March 21, 2024 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
OSE OSE IMMUNOTHERAPEUTICS SA
QIA QIAGEN NV
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
VLS VALNEVA SE
ALCAR CARMAT SA
GRF GRIFOLS S.A. CLASS A
ALINS INTRASENSE SA
ORY ORYZON GENOMICS
DIA DIASORIN S.P.A.
ADOC ADOCIA SA
ALVAL VALBIOTIS SA
BIM BIOMERIEUX SA
AFFLUENT MEDICAL SAS
ALMDP MEDESIS PHARMA SA
ALNFL NFL BIOSCIENCES SAS
ALTME TME PHARMA N.V.
ALVIN VINPAI
01/22/24 January 22, 2024 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
OSE OSE IMMUNOTHERAPEUTICS SA
QIA QIAGEN NV
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
VLS VALNEVA SE
ALCAR CARMAT SA
GRF GRIFOLS S.A. CLASS A
ALINS INTRASENSE SA
ORY ORYZON GENOMICS
DIA DIASORIN S.P.A.
ADOC ADOCIA SA
ALVAL VALBIOTIS SA
BIM BIOMERIEUX SA
AFFLUENT MEDICAL SAS
ALMDP MEDESIS PHARMA SA
ALNFL NFL BIOSCIENCES SAS
ALTME TME PHARMA N.V.
ALVIN VINPAI
01/22/24 January 22, 2024 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
10/30/23 October 30, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
10/18/23 October 18, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
10/06/23 October 6, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
07/12/23 July 12, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
07/07/23 July 7, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
06/09/23 June 9, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
06/05/23 June 5, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
04/18/23 April 18, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
04/03/23 April 3, 2023 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
10/27/22 October 27, 2022 1 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
10/11/22 October 11, 2022 1 EN
 PRESS RELEASE
Free
ALMDP Medesis Pharma ...

Medesis Pharma wishes to accelerate the development of its antinuclear...

Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy Montpellier (France), April, 5, 2022 - 8:45am – Medesis Pharma (ISIN: FR0010844464, Ticker: ALMDP), a pharmaceutical biotechnology company developing drug candidates with its proprietary buccal active ingredient delivery technology, Aonys®, publishes an information note on the three future drugs in development for the protection of large populations contam...

April 5, 2022 1 EN
 PRESS RELEASE
Free
ALMDP Medesis Pharma ...

Medesis Pharma souhaite accélérer le développement de ses produits ant...

Medesis Pharma souhaite accélérer le développement de ses produits antinucléaires et fait un point sur sa stratégie Medesis Pharma souhaite accélérer le développement de ses produits antinucléaires et fait un point sur sa stratégie Montpellier, le 5 avril 2022 - 8:45 – Medesis Pharma (ISIN: FR0010844464, Ticker: ALMDP)Medesis Pharma, une société de biotechnologie pharmaceutique développant des candidats-médicaments avec sa technologie propriétaire de libération d'actifs par voie buccale, Aonys®, partage une note d’information sur les trois candidats médicaments en développement pour la pr...

April 5, 2022 1 EN
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
11/23/21 November 23, 2021 6 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
11/17/21 November 17, 2021 21 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
09/22/21 September 22, 2021 6 FR
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
ALMDP MEDESIS PHARMA SA
09/02/21 September 2, 2021 7 FR
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest
Save

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search
Save

ResearchPool Subscriptions

Get the most out of your insights

Get in touch